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An adaptive mutation (E249G) within West Nile virus (WNV) NS4B gene was consistently recovered from replicon RNAs in C3H/He mouse
cells. The E249G is located at the C-terminal tail of NS4B predicted to be on the cytoplasmic side of the endoplasmic reticulum membrane. The
E249G substitution reduced replicon RNA synthesis. Compared with the wild-type NS4B, the E249G mutant protein exhibited a similar efficiency
in evasion of interferon-β response. Recombinant E249G virus exhibited smaller plaques, slower growth kinetics, and lower RNA synthesis than
the wild-type virus in a host-dependent manner, with the greatest difference in rodent cells (C3H/He and BHK-21) and the least difference in
mosquito cells (C3/36). Selection of revertants of E249G virus identified a second site mutation at residue 246, which could compensate for the
low replication phenotype in cell culture. These results demonstrate that distinct residues within the C-terminal tail of flavivirus NS4B are critical
for viral replication.
© 2006 Elsevier Inc. All rights reserved.Keywords: West Nile virus; NS4B; Flavivirus replicationIntroduction
West Nile Virus (WNV) is a member of the genus Flavivirus
within the family Flaviridae. Many viruses of this genus are
important arthropod-borne pathogens such as dengue virus
(DENV), yellow fever virus (YFV), Japanese encephalitis virus
(JEV), and the tick-borne encephalitis virus (TBEV) (Burke and
Monath, 2001).WNVis widely distributed in Africa, Europe, and
Asia. Since 1999, WNV has spread rapidly throughout the
western hemisphere, including the contiguous U.S., Canada,
Mexico, the Caribbean, and parts of South America. In North
America, the virus has caused significant human, equine, and
avian disease. Approximately 19,525 human cases and 771 deaths
of WN disease have been reported in the U.S. (http://www.cdc.⁎ Corresponding author. Wadsworth Center, New York State Department of
Health, 120 New Scotland Avenue, Albany, NY 12208, USA.
E-mail address: ship@wadsworth.org (P.-Y. Shi).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.11.012gov/ncidod/dvbid/westnile/surv&controlCaseCount06_detailed.
htm). Development of effective human vaccine and antiviral
therapy is a top priority for prevention and intervention of WNV
infection.
The plus-sense RNA genome of flavivirus is about 11,000
nucleotides long and consists of a single open reading frame
(ORF) flanked by 5′ and 3′ untranslated regions (UTRs). The
ORF encodes a long polyprotein which is co- and post-
translationally cleaved into 10 proteins by cellular and viral
proteases. Three structural proteins (C, prM, and E) are located
in the amino terminal region of the ORF, while seven non-
structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5) are located downstream (Brinton, 2002). The
structural proteins are mainly involved in viral particle
formation. The nonstructural proteins function on viral replica-
tion, virion assembly, and evasion of host antiviral immune
responses (Kummerer and Rice, 2002; Liu et al., 2005; Liu et al.,
2003; Munoz-Jordan et al., 2003; Pugachev et al., 2004).
Fig. 1. Identification of adaptive mutations in WNV replicon RNA persistently
replicating in C3H/He mouse cells. (A) WNV NeoRep (containing a deletion of
viral structural genes and a Neo gene driven by the EMCV IRES in the 3′ UTR)
was used to generate replicon-bearing C3H/He cell lines. (B) Adaptive
mutations were recovered from NeoRep RNAs that persistently replicated in
C3H/He cells. Sequencing results from four independent cell lines are shown.
The common A to G adaptive mutation at nucleotide position 7661 (resulting in
the E249G substitution of the NS4B) is shaded. (C) A five-transmembrane
topology of WNVNS4Bwas predicted by a protein folding program (Rost et al.,
1994). The E249G substitution is located at the C-terminal tail of NS4B on the
cytoplasmic side of ER. The black box represents the 2K fragment, which serves
as a signal sequence for the N-terminus of NS4B. White boxes indicate
transmembrane domains (TMD). The amino acid positions of the putative
TMDs are indicated. Sequence alignment of the last 10 amino acids of the NS4B
protein from different flaviviruses indicates that an acidic residue at position 249
is conserved among JE serogroup (shaded).
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containing a deletion of viral structural genes. Replicon systems
have been developed for many flaviviruses, including Kunjin
virus (KUNV) (Khromykh and Westaway, 1997), WNV
(Scholle et al., 2004; Shi et al., 2002a), YFV (Corver et al.,
2003; Jones et al., 2005; Molenkamp et al., 2003), DENV
(Alvarez et al., 2005; Holden et al., 2006; Pang et al., 2001; Puig-
Basagoiti et al., 2006), and TBEV (Gehrke et al., 2003). Cell
lines containing persistently replicating replicon of flaviviruses
have been established by selection of cells transfected with
replicon RNA expressing an antibiotic resistance gene. These
replicon-bearing cell lines are stable and useful for comple-
mentation analysis of replicase (Khromykh et al., 1999), virion
assembly (Khromykh et al., 1998; Puig-Basagoiti et al., 2005),
and antiviral drug screening (Lo et al., 2003b; Puig-Basagoiti et
al., 2006). One remarkable feature shared by the flavivirus
replicon-containing cells is that the persistent replication of viral
RNA does not cause cytopathic effect (CPE). In contrast, cells
infected with flavivirus usually exhibits apparent CPE. One
simple explanation for the non-cytopathic persistent replication
of flavivirus replicon might be due to the lack of viral structural
protein expression. Alternatively, adaptations for persistent
replication have occurred in replicon RNA and/or in host cells
during the selection of replicon-containing cell lines. In support
of the above hypotheses, Liu et al. showed that an Ala to Pro
substitution at amino acid 30 (A30P) of NS2A was recovered
from KUNV replicon; such A30P adaptation dramatically
reduced the NS2A-mediated inhibition of IFN-α/β response
and, consequently, favored persistent replication (Liu et al.,
2004, 2006). For the epidemic strain of WNV, Rossi et al.
recently reported that adaptations had accumulated in WNV
replicon that favored viral persistent replication (Rossi et al.,
2005); however, it is not known which adaptive mutations
confer the non-cytopathic replication, and more importantly,
how these adaptive substitutions affect WNV replication and
virulence in the context of full-length virus.
In this study, we show an adaptive mutation of Glu to Gly
at residue 249 (E249G) of NS4B that was consistently
accumulated in the epidemic strain of WNV replicon in C3H/
He mouse cells. The E249G mutation favored persistent
replication of replicon in C3H/He cells through reduction of
viral RNA replication. Recombinant WNV containing the
NS4B E249G mutation was attenuated both in cell culture
and in mice, and protected mice from challenge with wild-
type WNV. In cell culture, the low replication phenotype
mediated by the E249G mutation could be compensated by a
second site mutation at position 246, three amino acids
upstream of the original E249G substitution within the NS4B
protein.
Results
Noncytopathic replication of WNV replicon in C3H/He mouse
cells selects for adaptive mutations
To examine whether adaptive mutations would occur
during persistent replication of WNV replicon, we transfectedC3H/He mouse cells with replicon RNAs expressing a
neomycin phosphotransferase gene (NeoRep, Fig. 1A). After
selection of the transfected cells under G418 for 3 weeks,
distinct colonies became visible and were expanded into
several individual cell lines. The cell lines contained
persistently replicating NeoRep, as indicated by viral protein
expression (data not shown) and RNA replication (see
below), and did not exhibit apparent CPE. After culturing the
cell lines for over 2 months, we sequenced the complete
replicon RNA recovered from four independently derived
cell lines. Compared with the input NeoRep RNA, adaptive
mutations were observed in all persistently replicating RNAs
(Fig. 1B). Replicons from all four cell lines accumulated an
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resulting in a Glu to Gly mutation in amino acid 249
(E249G) of the NS4B gene. Replicons from cell lines 3 and
4 contained additional mutations in NS3 and NS5.
Quantification using real-time RT–PCR indicated a similar
level of replicon replication from different cell lines, approxi-
mately 8.7×105, 8.6×105, 8.2×105, and 7.6×105 of PFU-
equivalent RNA per μg of total cellular RNA for cell lines 1,
2, 3, and 4, respectively. These results indicate that NS4B
E249G could be a major adaptive mutation associated with
the non-cytopathic persistent replication of the NeoRep in
C3H/He cells.
The DENV and YFV NS4B proteins are associated with the
endoplasmic reticulum (ER) through five membrane-spanning
domains (Lin et al., 1993; Miller et al., 2006; Preugschat and
Strauss, 1991). A similar five-transmembrane topology of
WNV NS4B (Fig. 1C) was predicted by a protein folding
program (Rost et al., 1994). The adaptive E249G mutation is
located at the 7th amino acid from the C-terminus of the NS4B,
and is within a tail on the cytoplasmic side of the ER. Sequence
alignment of the cytoplasmic tail of various flaviviruses showedFig. 2. The NS4B E249G adaptive mutation confers an advantage in establishing p
(C3H/He, BHK-21, and Vero cells as indicated) were electroporated with wild-type o
1 mg/ml of G418 for about 3 weeks. G418-resistant cell colonies were fixed and stain
(6 cm) set of plates are shown to indicate the E249G-mediated improvement of colon
The relative sizes of the plates are proportionally displayed. One representative exper
He, BHK-21, and Vero cells after transfection of 1 μg of NeoRep RNA. The averagthat a negatively charged amino acid is conserved at position
249 among JE serogroup (Fig. 1C).
The NS4B E249G adaptive mutation improves the efficiency in
establishment of persistent replication in C3H/He and BHK-21
cells
We examined the role of the NS4B E249G mutation in
establishment of persistent replication by engineering the
change into the wild-type NeoRep RNA. Colony foci
formation showed that the E249G mutant replicon consis-
tently increased the number of G418-resistant cell colonies
by 2-fold compared with the wild-type replicon in C3H/He
and BHK-21 cells (Fig. 2A). In contrast, when tested in Vero
(monkey) cells, no substantial difference in the number of
cell colonies was observed between the wild-type and the
NS4B E249G mutant replicons (Fig. 2A). Fig. 2B sum-
marizes the efficiency of colony formation in C3H/He, BHK-
21, and Vero cells per microgram of transfected NeoRep
RNA. The results suggest that the NS4B E249G adaptation
slightly improved the establishment of cells containingersistent replication of NeoRep in C3H/He and BHK-21 cells. Three cell types
r NS4B E249G mutant NeoRep RNAs. The transfected cells were selected with
ed with Coomassie brilliant blue. For C3H/He cells, a large (10 cm) and a small
y formation. For BHK-21 and Vero cells, only the small sets of plates are shown.
iment of two is shown. (B) Summary of efficiency of colony formation in C3H/
e results of two independent experiments are presented.
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cells, but not in Vero cells.
The NS4B E249G mutation reduces WNV RNA synthesis in
C3H/He and BHK-21 cells
To study the function of the adaptive mutation in replicon
replication, we engineered the NS4B E249G into a luciferase-
reporting replicon of WNV (RlucRep, Fig. 3A) which can be
used to differentiate between viral translation and RNA
synthesis (Lo et al., 2003a). Equal amounts of wild-type andFig. 3. Effects of NS4B E249G mutation on viral translation and RNA synthesis
using a transient replicon assay. (A) A luciferase-reporting replicon of WNV
(RlucRep) was used to quantify the effects of NS4Bmutation on viral translation
and RNA synthesis. (B) C3H/He, BHK-21, and Vero cells were electroporated
with equal amounts of wild-type (●) and mutant RlucRep (○) RNAs, and
assayed for luciferase activities at indicated time points. Average results from
three independent experiments are presented.mutant RlucRep RNAs were transfected into three types of cells
(C3H/He, Vero, and BHK-21) and assayed for luciferase
activities at indicated time points post-transfection. After
transfection with wild-type or mutant RlucRep, all three cell
types exhibited a two-peak luciferase pattern: the first peak
(representing translation of input replicon RNA) occurred
during the initial 8 h p.t.; the second peak (representing
translation of the newly synthesized replicon RNA) appeared
after 24 or 48 h p.t. (Fig. 3B). We and others have previously
shown that the luciferase signals collected at 72 and 96 h p.t.
reliably reflect RNA synthesis of the RlucRep (Alvarez et al.,
2005; Lo et al., 2003a). In each of the three tested cell types,
luciferase activities of the first peak derived from the wild-type
RlucRep were slightly higher than those derived from the
mutant replicon. For the second luciferase peak, signals derived
from the wild-type replicon were higher than those derived from
the mutant RlucRep in C3H/He and BHK-21 cells. For
example, at 72 h p.t., the luciferase signals from wild-type
RlucRep were 10-fold higher than those from the mutant
replicon in both C3H/He and BHK-21 cells. In contrast, the
difference of the second luciferase peak between the wild-type
and mutant RlucRep was less dramatic in Vero cells: less than 3-
and 2-fold difference at 72 and 96 h p.t., respectively (Fig. 3B).
Overall, the results suggest that the NS4B E249G mutation does
not substantially affect viral translation, but reduces viral RNA
synthesis in C3H/He and BHK-21 cells, and to a less extent in
Vero cells.
The E249G mutation does not affect the NS4B-mediated
inhibition of IFN response
Since flavivirus NS4B inhibits host IFN response (Munoz-
Jordan et al., 2003), it is possible that adaptive mutation(s)
could be selected in NS4B to abolish its antagonism of IFN
response. The resulting mutant replicons would be more
sensitive to host antiviral suppression, leading to non-cytopathic
persistent replication. To test this possibility, we co-transfected
Vero cells with two plasmids, one plasmid expressing a GFP–
STAT-1 fusion protein, and the other plasmid expressing WNV
NS4B. The NS4B construct contained the C-terminal 23 amino
acids of the upstream NS4A (for proper translocation of the
NS4B on ER membrane) and a C-terminal MYC-tag (Fig. 4A).
Upon treatment of the transfected cells with IFN-β, GFP–
STAT-1 translocated into nucleus in cells without co-expression
of WNV NS4B. In contrast, GFP–STAT-1 remained in
cytoplasm in cells co-expressing the WNV NS4B. As positive
controls, expression of NS4B from DENV-2 was also shown to
block nucleus translocation of GFP–STAT-1 (Fig. 4A) (Munoz-
Jordan et al., 2003). These results confirmed previous studies
that WNV NS4B inhibits STAT-1 nuclear translocation (Guo
et al., 2005; Liu et al., 2005; Munoz-Jordan et al., 2005). A
similar blockage of GFP–STAT-1 nuclear translocation was
observed when the E249G mutant NS4B was tested (Fig. 4A),
indicating the mutation does not affect the NS4B-mediated
inhibition of STAT-1 nuclear translocation.
Next, we used Newcastle disease virus expressing GFP
(NDV–GFP) to quantify any potential difference in antagonizing
Fig. 4. The E249G mutation does not affect the NS4B-mediated inhibition of IFN response. (A) Vero cells were co-transfected with two plasmids (expressing GFP–
STAT-1 fusion protein and NS4B protein from WNVor DENV-2 virus), treated with IFN-β, and analyzed for nuclear translocation of GFP–STAT-1. Both wild-type
(NS4B-MYC) and mutant NS4B (NS4Bmut-MYC) proteins of WNV were detected through their C-terminal MYC-tag. DENV-2 NS4B (NS4B-HA) was detected
through its C-terminal HA-tag. DAPI was used to stain nuclear chromatin of cells. (B) Vero cells were transfected with empty expression vector pcDNA or plasmid
expressing wild-type NS4B (NS4B) or mutant NS4B (NS4Bmut), treated or mock-treated with IFN-β, infected with NDV-GFP, and quantified for GFP signals in a
luminescence spectrometer. Fluorescence values were expressed as percentage of maximum fluorescence obtained in the absence of IFN (set as 100%). All values were
subtracted of values obtained with empty plasmid in the presence of IFN. Average results of two experiments are shown.
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protein. As shown in Fig. 4B, no GFP signal was detected in Vero
cells that were transfected with empty expression plasmid, treated
with IFN, and infected with NDV–GFP. In contrast, substantial
GFP expression was observed in cells when transfected with
plasmid expressing either wild-type or mutant NS4B protein, and
theGFP signals were about 74% and 68%of the signals from cells
that were not treated with IFN (set as 100%), respectively. These
results suggest that the adaptive E249G mutation does not
substantially interfere with the NS4B-mediated inhibition of
STAT-1-mediated IFN pathway.
Characterization of WNV containing the NS4B E249G
mutation in cell culture
To study the effect of NS4B mutation on replication in the
context of full-length virus, we introduced the mutation into aninfectious clone of an epidemic WNV strain (Shi et al., 2002b).
Initially, we examined whether the NS4B mutation affects the
specific infectivity of the full-length RNA. Transfection of
BHK-21 cells with 1 μg of wild-type and mutant RNA yielded
9×104 PFU and 11×104 PFU, respectively, indicating the
mutant RNA was as infectious as the wild-type RNA.
We compared the growth kinetics between the wild-type and
mutant viruses in five host cell types. C3H/He (mouse), BHK-
21 (hamster), Vero (monkey), C6/36 (mosquito), and PDE
(duck) were infected with 0.1 MOI of wild-type or mutant
WNV, and virus yields were titered at indicated time points
post-infection (Fig. 5). Among the tested cell types, Vero and
BHK-21 cells are known to be defective in IFN production
(Mosca and Pitha, 1986; Otsuki et al., 1979). In C3H/He and
BHK-21 cells, the wild-type virus consistently produced higher
levels of virus (≥10-fold) than the mutant at ≥24 h post-
infection. In Vero cells, the difference in viral yields between the
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other four tested cell types, the C6/36 cells supported much
slower virus growth, and the wild-type virus yielded onlyFig. 5. Comparison of growth kinetics of wild-type and NS4B mutant WNV in
different host cells. C3H/He (mouse), BHK-21 (hamster), Vero (monkey), C6/36
(mosquito), and PDE (duck) cells were infected with wild-type (●) or mutant
(○) WNVat an MOI of 0.1. Virus yields were quantified using standard plaque
assays at indicated time points post-infection. An average of two independent
experiments is shown.slightly higher titer (≤2-fold) than the mutant virus. In PDE
cells, the difference in virus yields between the two viruses was
more dramatic than those in Vero and C3/36 cells, but slightly
less than those in C3H/He and BHK-21 cells. The above results
demonstrate that the NS4B E249G mutation reduces WNV
replication in a host-dependent manner, with the greatest
difference in rodent cells (C3H/He and BHK) and the least
difference in mosquito cells (C3/36).
To examine if the reduction of viral replication correlates to
the extent of CPE of infected cells, we performed an MTTassay
to measure the viability of BHK cells infected with the wild-
type or mutant virus (Fig. 6). Although infections with both
wild-type and mutant viruses resulted in CPE, the rate of cell
death in wild-type virus-infected cells was more dramatic than
that in mutant virus-infected cells. The MTT results agreed with
the extent of CPE observed by microscopy (data not shown).
These data demonstrate that the reduced level of viral
replication conferred by the NS4B mutation could lead to a
decreased level of CPE in cell culture.
Selection and analysis of NS4B revertant viruses
We cultured the E249G mutant virus in BHK-21 cells to
examine if revertant isolates could be obtained. Passaging the
E249G mutant virus yielded isolates with big plaque sizes
similar to the wild-type virus within the background of viruses
with small plaque phenotype similar to the original E249G virus
(Data not shown). The emerged viruses with big plaque sizes
were potential revertant isolates. A total of 10 independent
isolates, from two transfection experiments, were plaque
purified, amplified, and sequenced within the NS4A to NS5
regions. Remarkably, besides the original E249G mutation, all
isolates contained one additional change at amino acid 246
within the NS4B gene. Among those, 2 isolates contained a
change from Lys246 (AAG) to Met (AUG), 3 isolates to Asn
(AAC), and 5 isolates to Gln (CAG). These results indicate that
the small plaque phenotype of E249G mutant could be restored
to big plaque by a compensatory mutation at residue 246 within
the NS4B protein.
Since we did not sequence the complete genome of the
revertant isolates, changes other than the mutation at amino acid
246 could account for the plaque size reversion. To exclude this
possibility, we chose K246Q as an example to examine the
function of the second site mutation. Recombinant viruses
containing the K246Q+E249G double mutations or K246Q
single substitution were generated and analyzed for plaque
morphology, growth kinetics, and viral RNA synthesis. The
K246Q+E249G virus exhibited bigger plaques than the
original E249G virus, and the K246Q virus showed a plaque
size similar to the wild-type virus (Fig. 7B). Comparable growth
Fig. 7. Analyses of NS4B mutant and revertant viruses in cell culture. (A)
Amino acid sequences of the C-terminal cytoplasmic tail of WNV NS4B
protein. The original mutation E249G, single compensatory mutation K246Q,
and double mutation K246Q+E249G are indicated. Plaque morphology (B),
growth kinetics on C3H/He cells (C), and viral RNA synthesis on C3H/He cells
(D) are compared among the recombinant viruses containing wild-type, K246Q,
E249G, and K246Q+E249G sequence of NS4B. See Materials and methods for
details.
Fig. 6. Comparison of cell viability of BHK-21 cells infected with wild-type and
NS4B mutant WNV. BHK-21 cells were infected with wild-type (dark grey) and
NS4B mutant (light grey) WNVat an MOI of 0.1, and assayed for cell viability
using an MTT assay at indicated time points. Mock-infected cells (black bars)
were set at 100% for comparison at each time point.
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K246Q+E249G viruses, all of which showed a higher growth
rate than the E249G virus (Fig. 7C). For RNA synthesis, similar
levels of viral RNAwere detected up to 12 p.i., after which the
wild-type, mutant K246Q, and K246Q+E249G viruses yielded
more RNA than that of E249G virus (Fig. 4D). These results
demonstrate that the K246Q is a major second site mutation
which can compensate for the lower RNA replication
phenotype.
The NS4B E249G mutant WNV is attenuated and can protect
mice from challenge with wild-type virus
The virulence phenotypes of the wild-type and mutant WNV
were compared in an adult C3H mouse model by inoculating
103 PFU subcutaneously (s.c.). Table 1 summarizes the disease
phenotypes. Higher rates of morbidity and mortality were
observed in mice inoculated with the wild-type viruses than
those inoculated with the mutant viruses, K246Q, E249G, and
K246Q+E249G. The differences in survival between the wild-
type and mutants were statistically significant with p-values of
0.004, 0.002, and 0.0005 compared to wild-type virus for
K246Q, E249G, and K246Q+E249G, respectively. A delayed
disease onset and increased survival time were also observed for
mice inoculated with the mutant viruses compared to the wild-
type virus (Table 1). Thus, all three mutants are significantly
attenuated in mice. A productive WNV infection was demon-
strated in all surviving mice inoculated with virus by the
detection of positive WNV-antibody on 28 days post-inocula-
tion (data not shown); therefore, a decreased infection rate does
not explain the attenuation of the mutant viruses.
Next, we tested if the mice that survived the initial
inoculation were protected from a high dose challenge of
WNV. Surviving mice were inoculated with 106 PFU of wild-
type WNV intraperitoneally. Remarkably, after challenge, no
morbidity or mortality was observed in mice that survived the
initial inoculation with mutant viruses. In contrast, the mice
previously inoculated with diluent showed 88% and 38%
morbidity and mortality, respectively. An analysis was per-
formed combining the three groups of mice inoculated with
Table 1
WNV NS4B mutants are attenuated compared to wild-type WNV in mice
Initial inoculum Initial inoculation results a Challenge results b
Morbidity,
# sick/total
Average day
of onset (SD)
Mortality
# dead/total
ASTc (SD) Challenge inoculum Morbidity,
# sick/total
Mortality,
# dead/total
Diluent 0/12 NA 0/12 NA Diluent 0/4 0/4
WNV-wt 7/8 3/8
WNV K246Q 6/8 9.2 (1.94) 5/8 12.2 (4.71) WNV-wt 0/3 0/3
WNV E249G 4/8 8.3 (0.96) 4/8 10.8 (2.22) WNV-wt 0/4 0/4
WNV K246Q+E249G 5/8 9.4 (2.07) 3/8 12.7 (5.03) WNV-wt 0/5 0/5
WNV wild-type 8/8 7.3 (0.46) 8/8 8.6 (1.41) WNV-wt NA NA
a Six-week-old C3H female mice were inoculated subcutaneously in the left rear footpad with 103 PFU or diluent alone and monitored for weight loss and clinical
signs.
b Surviving mice were challenged on day 29 post-inoculation with wild-typeWNV by inoculating 106 PFU intraperitoneally. Prior to challenge, surviving mice were
bled on day 28 post-inoculation and tested for WNV specific antibody by ELISA; all WNV-inoculated mice were seropositive, and mock-inoculated mice were
seronegative.
c AST=average survival time calculated for mice that died only. SD=standard deviation. NA=not applicable.
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protected compared to the eight control mice (p-value=0.02).
Overall, the results demonstrate that the mutant viruses are
attenuated and can be used to protect mice from WN disease;
however, the second site mutation K246Q alone or in
combination with mutation E249G does not restore the wild-
type virulence in vivo.
Discussion
The study describes and characterizes a mouse cell-adapted
mutation in NS4B gene that could attenuate WNV virulence
through suppression of viral RNA synthesis. Our data agree with
a previous report that RNA replication level is reduced in WNV
replicon-containing cells (Rossi et al., 2005). We have extended
the study by defining a specific mutation (NS4B E249G) that
confers the reduced replication phenotype (Fig. 1). The adaptive
E249Gmutation is located within the C-terminal tail of NS4B on
the cytoplasmic side of the ER. Next, we have characterized this
mutation in the context of full-length virus both in cell culture
and in mice. Similar to the replicon results (Fig. 3), recombinant
virus containing the NS4B E249G mutation exhibited a lower
level of replication, as evidenced by smaller plaque size, slower
growth kinetics, and RNA synthesis in cell culture (Fig. 7). The
attenuated replication of the mutant virus resulted in less CPE of
infected cells than the wild-type virus (Fig. 6). Finally, we
demonstrated that the lower level of replication of the E249G
virus in cell culture could be restored by a compensatory
mutation of K246Q within NS4B (Fig. 7).
It should be noted that the NS4B E249G mutation described
in this study was also recovered from three bird isolates of
WNV collected in Texas, USA in 2003 (Davis et al., 2004). The
virulence of these bird isolates were significantly reduced in
mice in comparison with the New York strain 99, although
specific mutations responsible for the reduced virulence were
not defined (Davis et al., 2004). Our results suggest that the
NS4B E249G mutation could contribute to the attenuation of
those bird isolates, but we could not exclude the possibility that
other mutations also contribute to the attenuated virulence.Similar to our results, during selection of non-cytopathic
Sindbis virus replicon, a single amino acid substitution was
recovered in the C-terminal portion of nsP2 (viral helicase–
protease) that reduces viral RNA replication (Frolov et al.,
1999). Sindbis replicons containing such nsP2 mutation under-
went non-cytopathic persistent replication, and infection of cells
with viruses containing this mutation generated a lower level of
viral RNA and less CPE (Frolov et al., 1999). In bovine viral
diarrhea virus (BVDV), a mutation in NS4B was found to be
able to switch a cytopathic isolate to a non-cytopathic one (Qu
et al., 2001). In contrast to reducing RNA replication in WNV
and Sindbis virus, the NS4B mutation found in BVDV did not
seem to suppress viral RNA synthesis, but it increased the levels
of uncleaved NS2–3 relative to NS3 (the hallmark of non-
cytopathic infection of BVDV). In contrast, selection of
hepatitis C virus (HCV) replicon in Huh-7 cells renders
adaptive mutations, often in NS5A, that increased RNA
replication and Neo-transduction efficiency (Blight et al.,
2000; Lohmann et al., 2001). Many adaptive mutations in
NS5A are found to decrease the hyperphosphorylation of itself
for higher replication of HCV replicon (Blight et al., 2003;
Lohmann et al., 2003). Some adaptive NS5A mutations could
alter the ability of the protein to bind and suppress the cellular
protein kinase R (PKR) (Pflugheber et al., 2002), which is a key
enzyme in the antiviral action of the IFN-α/β system.
Conversely, KUNV replicon accumulated an amino acid
substitution (A30P) in NS2A that could reduce the NS2A-
mediated inhibition of IFN response, resulting in persistent
replication (Liu et al., 2004; Liu et al., 2006). Since KUNV is an
attenuated subtype of WNV, it is surprising that no NS2A
mutations were found in our study. This could be due to
different cell types and virulence of viruses used in the two
studies. Nevertheless, the above examples suggest that RNA
viruses develop different strategies to confer non-cytopathic
replication.
Colony formation of cells containing Neo-expressing
replicon of WNV requires a balance between viral replication
and host response, which could suppress viral replication. On
one side, cells need a certain level of replicon replication to
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antibiotic selection. On the other side, over replication of
replicon generates a high level of viral proteins that could lead
to apoptosis of host cells. Although the detailed mechanism of
flavivirus-induced apoptosis has yet to be determined, cell death
is reported to be mediated through antiviral response (Roulston
et al., 1999) and through individual flavivirus proteins,
including C (Yang et al., 2002), E (Duarte dos Santos et al.,
2000), and NS3 (Preugschat et al., 1990). The reduced level of
RNA replication of the NS4B E249G mutant WNV would
result in a lower level of viral protein expression or a delay of
virus spread in cells, leading to less cytopathic effect (Fig. 6).
Different cell types may support and tolerate different levels of
WNV replication. This may explain why the mutant NeoRep
(containing the NS4B E249G) improved the efficiency of cell
colony formation by 2-fold in C3H/He and BHK-21 cells,
whereas no improvement was observed in Vero cells (Fig. 2).
Moreover, Vero cells might be more resistant to WNV-induced
apoptosis since they are known to be also more resistant to
apoptosis induced by other viruses, such as herpes simplex virus
(Aubert and Blaho, 1999).
Three functions have been previously suggested for
flavivirus NS4B and could be potentially affected by the
E249G mutation to confer the attenuation of WNV. (i) Viral
RNA replication. Our results using transient luciferase-
reporting replicon (Fig. 3), together with the real-time
quantification of viral RNA in infected cells (Fig. 7D),
clearly demonstrate that the NS4B E249G mutation reduces
viral RNA synthesis. The level of mutation-mediated reduc-
tion of RNA synthesis varied among host cell types: more
significant difference in C3H/He and BHK-21 cells (>10-fold
reduction in luciferase signal) than that in Vero cells (<2-fold
decrease in luciferase signal). In line with the replicon results,
the difference in growth kinetics between the wild-type and
mutant viruses was also host cell-dependent: in the order of
rodent (C3H/He and BHK-21), avian (PDE), primate (Vero),
and mosquito (C6/36) cells from more to less difference (Fig.
6). Since Vero cells have a deletion of the IFN-β gene (Mosca
and Pitha, 1986) and BHK-21 cells are defective in IFN
production (Otsuki et al., 1979), the growth differences
between the wild-type and mutant viruses among various cell
types are not likely due to differences in IFN production.
These results indicate that the E249 residue of NS4B may
interact, directly or indirectly, with a cellular factor that is
important for viral replication. The putative cellular factor
may vary slightly among hosts and, therefore, confer different
sensitivity to the NS4B E249G substitution. Similar to our
observation, a P101L mutation in DENV-4 NS4B was
previously shown to enhance viral replication in Vero and
human Huh-7 cells, but decrease replication in mosquito C6/
36 cells (Hanley et al., 2003). (ii) Suppression of host innate
immune response. Since flavivirus NS4B is a potent
suppressor of host antiviral immune responses (Munoz-Jordan
et al., 2003), mutations that weaken the NS4B-mediated
suppression of IFN-α/β response could result in a mutant
WNV more sensitive to IFN inhibition and, therefore,
yielding a lower level of viral RNA during infection. Sucha mechanism was recently shown in NS2A to facilitate
KUNV persistent infection (discussed above) (Liu et al.,
2004, 2006). A similar mechanism was also proposed for the
establishment of persistent infection by the paramyxo simian
virus 5 (Chatziandreou et al., 2002). However, the E249G
mutation identified in this study did not seem to interfere with
the NS4B-mediated antagonism of IFN response (Fig. 4).
These results concur with a recent study that the N-terminal
125 amino acids of the NS4B are sufficient for inhibition of
IFN-α/β signaling (whereas our mutation is located at the C-
terminal tail of the protein) (Munoz-Jordan et al., 2005). (iii)
Virion assembly. Sequencing of chimeric YFV containing
DENV prM-E genes or chimeric DENV-4 virus containing
WNV prM-E genes showed accumulation of mutations in the
NS4B region, indicating that NS4B may be critical for
nucleocapsid-envelope interaction during flavivirus assembly
(Pletnev et al., 2002; Pugachev et al., 2004). Based on the
transmembrane topology of the WNV NS4B, these adapta-
tions were clustered at 3rd and 4th membrane-spanning
domains, upstream of the E249G described in this study (Fig.
1C). Since our NS4B mutation was derived from a replicon
system where no viral assembly is involved, it is unlikely that
the E249G substitution affects virion assembly.
Selection of revertant isolates of E269G virus allowed us
to identify compensatory mutations from K to M, N, or Q at
amino acid 246 within NS4B. Using K246Q mutation as an
example, we showed that recombinant viruses containing the
K246Q+E249G double substitutions restored the wild-type
plaque size, growth kinetics, and RNA synthesis level.
Interestingly, recombinant virus with the compensatory
mutation K246Q alone also exhibited the wild-type in vitro
phenotype (Fig. 7). In line with the cell culture results, the
E249G mutant virus was attenuated in mice and can protect
mice from challenge with wild-type virus (Table 1). However,
the double mutant K246Q+E249G virus did not restore the
wild-type virulence in vivo. The discrepancy between the in
vitro and in vivo results remains elusive and suggests that in
vitro replication alone does not confer virulence. Never-
theless, our recombinant virus results clearly demonstrate that
distinct residues within the C-terminal tail of flavivirus NS4B
are critical for flavivirus replication.
Materials and methods
Cells and viruses
C3H/He (mouse embryo fibroblast), BHK-21 (baby hamster
kidney), and Vero (African green monkey) cells were
maintained in Dulbecco's modification of minimal essential
medium (DMEM) with 10% fetal bovine serum (FBS) in 5%
CO2 at 37 °C. PDE (Peking Duck Embryo) cells were cultured
in MEM medium with 10% FBS, 1.5 g/L NaHCO3, 1% non-
essential amino acids (NEAA), 2 mM L-glutamine, and 1 mM
MEM sodium pyruvate in 5% CO2 at 37 °C. C6/36 (mosquito)
cells were maintained in Eagle's minimal essential medium
(EMEM) with 10% FBS, 1.5 g/L sodium bicarbonate and 1%
NEAA at 28 °C. The C3H/He (Darnell and Koprowski, 1974)
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at Georgia State University. Vero, PDE, and C6/36 cells were
purchased from American Type Culture Collection (ATCC,
Manassas, VA). Wild-type and mutant WNV was produced
from an infectious cDNA clone (Shi et al., 2002b). All viruses
were quantified by plaque assays using Vero cells as previously
described (Puig-Basagoiti et al., 2005).
Plasmid construction
cDNA clones of full-length WNV and replicons containing
a Renilla luciferase (RlucRep) or neomycin phosphotransfer-
ase (NeoRep) were constructed previously (Deas et al., 2005;
Lo et al., 2003a; Shi et al., 2002a). A similar procedure was
followed to engineer the NS4B mutations into the infectious
clone and replicons. A DNA fragment containing a specific
NS4B mutation (an A to G substitution at nucleotide 7661 for
amino acid E249G mutation or an A to C substitution at
nucleotide 7651 for amino acid K246Q change of NS4B) was
prepared through a standard over-lapping PCR, and cloned
into wild-type full-length and replicon cDNA plasmids
through the unique BsiWI and SpeI at nucleotide positions
5780 and 8022 (GenBank Accession Number AF404756),
respectively.
Two plasmids were constructed to express wild-type and
mutant E249G NS4B proteins. DNA fragments containing the
last 69 nucleotides of the NS4A gene (to ensure the correct
intracellular membrane localization of NS4B) followed by the
full-length NS4B gene were PCR-amplified using wild-type
and NS4B mutant RlucRep (described above) as templates,
and cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad,
CA) at BamHI and EcoRI sites, resulting in pcDNA-WNV-
NS4B-Myc (wild-type) and pcDNA-WNV-NS4Bmut-Myc
(mutant). In addition, the Kozak sequence was inserted at
the amino terminus of the NS4A sequence to enhance protein
expression and a c-MYC epitope (9 amino acids) was inserted
at the C-terminus of the NS4B to detect its expression. All
constructs were confirmed by DNA sequencing.
Generation of replicon-containing cell lines and sequencing of
replicon RNAs
C3H/He cells were transfected with NeoRep RNA (Fig. 1A)
and selected with neomycin (G418). Briefly, 8×106 cells in
0.8 ml of cold phosphate-buffered saline (PBS) were electro-
porated with 10 μg of NeoRep RNA in a 0.4-cm electrode gap
cuvette with the GenePulser apparatus (Bio-Rad, Hercules, CA)
at settings of 0.85 kV and 25 μF, pulsing three times, with no
pulse controller. After 10 min of recovery, cells were re-
suspended in 25 ml medium, and 4 ml of cell suspension were
seeded in 60-mm-diameter dishes. After 24 h post-transfection
(p.t.), the seeded cells were cultured in medium containing
1 mg/ml of G418, and the medium was replenished every 3–
4 days. After 3 weeks of selection, individual foci were isolated
using sterile cloning disks (Bel-Art Products, Pequannock, NJ)
previously soaked with 0.25% trypsin. The disks with the
absorbed cells were then transferred into a 24-well plate forfurther expansion. The NeoRep-containing cell lines were
cultured in DMEMwith 10% FBS and 1 mg/ml G418. A similar
procedure was performed to determine the efficiency of colony
formation for the wild-type and mutant E249G NeoRep, except
that 4 ml of 1:10 serial dilutions of transformed cell suspension
were seeded. After 2–3 weeks of G418 selection, cell colonies
were stained with Coomassie brilliant blue. To identify adaptive
mutations, we cultured individual cell lines in the presence of
1 mg/ml of G418 for over 2 months and extracted total cellular
RNAs using RNeasy kits (Qiagen). Viral RNAs were then
amplified through RT–PCR using the One-Step RT–PCR kits
(Invitrogen). The PCR products were directly subjected to DNA
sequencing.
Transient replicon assay
RlucRep RNAs were in vitro transcribed using mMES-
SAGE mMACHINE kits (Ambion, Austin, TX) as previously
reported (Shi et al., 2002b). An equal amount (10 μg) of
wild-type and NS4B mutant RlucRep RNAs were electro-
porated into C3H/He, BHK-21, or Vero cells as described
above. The transfected cells were re-suspended in 25 ml of
DMEM with 10% FBS. For data points at <48 h p.t., 2.5 ml
of the cell suspension were seeded per well in 6-well plates.
For data points at ≥48 h p.t., 1 ml of the cell suspension was
seeded per well to avoid overgrowing of the cells. At the
indicated time points, cells were washed with PBS, lysed,
stored at −80 °C, and assayed for luciferase activity as
previously described (Lo et al., 2003). All data points were
performed in duplicates or triplicates.
Specific infectivity and cytopathic assays
BHK-21 cells were transfected with wild-type and mutant
genomic-length RNAs prepared from cDNA plasmids as
described above. The transfected cells were adjusted to a
concentration of 3.1×105 cells/ml. One ml of a series of 1:10
dilutions of the transfected cells was seeded onto nearly
confluent Vero cells (6×105 per well were seeded in a 6-well
plate 3 days in advance). The seeded cells were allowed to
attach to the plates for 7 to 10 h before the first layer of agar was
added, as previously described (Puig-Basagoiti et al., 2005).
After incubation of the plates for 2 days, a second layer
containing neutral red was added. Plaques were counted after
incubation of the plates for another 12 to 18 h. The specific
infectivity was calculated as the number of plaque forming unit
(PFU) per microgram of transfected RNA. For comparison of
the CPE caused by infections of wild-type and NS4B mutant
viruses, BHK-21 cells were seeded in 96-well plates, infected
with wild-type or mutant virus at an MOI of 0.1, and monitored
for cell viability at indicated time post-infection (p.i.) using a
standard MTT assay (Puig-Basagoiti et al., 2005). Different
number of cells ranging from 1.5×103 to 8×104 were seeded
per well to ensure that, at the time of MTT assay, the mock-
infected cells were not overgrown. The CPE caused by viral
infections was estimated as the percentage of viable cells
compared with the mock-infected cells.
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Cells grown in 12-well plates were infected with WNV
(0.1 MOI) for 1 h, after which the viral inocula were removed.
The infected cells were washed twice with PBS and cultured
with 1 ml of fresh medium per well. The culture medium was
collected at various time points, stored at −80 °C, and assayed
for virus titers using standard plaque assays (Puig-Basagoiti et
al., 2006). The cell numbers per well and the incubation time
prior to infection differed for various cell types: 6×105 of C3H/
He cells, 3×105 of BHK-21 or Vero cells, and 2.4×106 of C6/
36 cells per well. The C3H/He and C6/36 cells were infected at
12 h post-seeding, while the BHK-21 and Vero cells were
infected at 72 h post-seeding.
To compare RNA synthesis between wild-type and mutant
WNV, C3H/He cells were synchronously infected with wild-
type and mutant WNV by incubating the cells with viruses at an
MOI of 10 at 4 °C for 1 h. The cells were then washed three
times with PBS, replenished with medium, and cultured at
37 °C. At various time points post-infection, total cellular RNA
was extracted with TRIzol (Invitrogen, Carlsbad, CA) and
quantified by NanoDrop Spectrophotometer. Equal amounts of
extracted RNA (1 μg) was measured for viral RNA using a
primer/probe set targeting the NS5 gene of WNVon 7500 RT–
PCR system (Applied Biosystems) as described previously (Shi
et al., 2001).
Selection and analyses of NS4B revertant viruses
To select revertant isolates, NS4B E249G mutant virus with
small plaque phenotype was cultured in BHK-21 cells for three
passages (total 9 days). The resulting viruses exhibited mixed
plaque sizes. Plaques with wild-type large sizes were purified
and amplified in BHK-21 cells. RT–PCR products amplified
from the extracted viral RNA were directly sequenced and a
second site mutation at amino acid 246 was identified in NS4B.
Recombinant viruses containing the original E249G, compen-
satory K246Q, or both mutations were prepared and analyzed as
described above.
STAT-1 nuclear translocation assay
Vero cells were cultured in DMEM with 10% FBS to 80%
confluence and transfected by Lipofectamine 2000 (Invitrogen).
Each transfection of 5×106 cells contained two plasmids: 2 μg
of pCAGGS-STAT1-GFP and 4.0 μg of pCAGGS-DENV2-
NS4B-HA, pcDNA-WNV-NS4B-MYC, or pcDNA-WNV-
NS4Bmut-MYC. The pCAGGS-STAT1-GFP and pCAGGS-
DENV2-NS4B-HA constructs were described previously
(Munoz-Jordan et al., 2005). At 24 h p.t., cells were mock-
treated or treated with 1,000 U of human IFN-β (Calbiochem,
San Diego, CA). Nuclear translocation of GFP–STAT-1 was
visualized under the fluorescence microscope at 30 min post-
treatment. Cells were fixed and permeabilized in cold methanol.
HA-tag mouse antibody or MYC-tag monoclonal antibodies
(Sigma, St. Louis, MO) were used as primary antibodies. Texas
red anti-mouse (Jackson Immunochemicals, West Grove, PA)was used as secondary antibody to visualized NS4B proteins.
Nuclear chromatin staining was performed by incubation in a
PBS solution containing 0.5 mg/ml 4′,6-diamidino-2-pheny-
lindole (DAPI; Sigma).
WNV NS4B-mediated promotion of replication of Newcastle
disease virus expressing GFP (NDV-GFP) in the presence of IFN
NDV-GFP was used to quantify the NS4B-mediated
antagonism of IFN response (Munoz-Jordan et al., 2005). Vero
cells were transfected with 4 μg of pcDNA-WNV-NS4B-MYC,
pcDNA-WNV-NS4Bmut-MYC, or empty vector pcDNA as
described above. About 12 h later, cells were washed and
incubated in DMEM containing 1,000 U of human IFN-β and
incubated for 24 h. Transfected cells were then washed with PBS
and infected with NDV-GFP at an MOI of 2. After 1 h of
infection at room temperature, inoculum was aspirated and cells
were maintained in DMEM supplemented with 5% FBS for 24 h
before visualization under a fluorescent microscope. Duplicate
samples were washed with PBS, detached with trypsin, and
resuspended in 1 ml of PBS. Green fluorescence was quantified
at an emission of 380 nm in a luminescence spectrometer (Perki
Elmer LS55). Fluorescence values were expressed as percentage
of maximum fluorescence obtained in the absence of IFN. All
values were subtracted of values obtained with empty plasmid
pcDNA in the presence of IFN.
Virulence analysis in mice
Five-week-old, female C3H/HeN (C3H) mice were purchased
fromTaconic (Germantown,NY), acclimatized for at least 1 week
in the biosafety-level-3 vivarium, and given food and water ad
libitum. The mice were inoculated at 6 to 7 weeks of age
subcutaneously in the left rear footpadwith 10-μl inoculum, using
a 30 G needle and 100 μl glass syringe (Hamilton, Reno, NV).
Twelve mice were inoculated with diluent alone, and eight mice
per group were inoculated with wild-type or mutant WNVat 103
PFU. The diluent for viral inocula was endotoxin-free PBS (tissue
culture grade; Invitrogen) with 1% FBS. All mice were observed
for clinical disease daily for the entire study, and all mice were
weighed daily for at least 14 days post-inoculation and thrice
weekly for the duration of the study. Clinical signs included
ruffled fur, ataxia, weakness, and weight loss. Morbidity was
defined as clinical signs for at least 2 days and/or greater than 9%
weight loss. Mice that exhibited severe disease were euthanized.
Surviving mice were bled at 28 days post-inoculation, and sera
were tested for WNV-specific antibodies by ELISA. Surviving
mice were challenged at 34 days after the initial inoculation. For
challenge studies, mice were inoculated intraperitoneally (IP)
with 106 PFU of wild-type WNV in 100 μl, using a 25 G needle
and 1 cm3 syringe. Mice were monitored and weighed as
described above for 28 days post-challenge. All studies were
approved by the Institutional Animal Care and Use Committee of
the Wadsworth Center and followed criteria established by the
National Institutes of Health. Survival curves were analyzed with
a Logrank test using GraphPad Prism (GraphPad Software, Inc.,
San Diego, CA).
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